Test sensitivity in the European prostate cancer screening trial: Results from Finland, Sweden, and the Netherlands

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 7, 2009, Pages 2000-2005

  Auvinen, Anssi ^a   Raitanen, Jani ^a   Moss, Sue ^b   De Koning, Harry J ^c   Hugosson, Jonas ^d,e   Tammela, Teuvo ^f   Roobol, Monique ^g   Lilja, Hans ^d   Hakama, Matti ^a,h  

^a UNIVERSITY OF TAMPERE   (Finland)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e LUND UNIVERSITY   (Sweden)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h FINNISH CANCER REGISTRY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; EUROPE; FALSE NEGATIVE RESULT; FINLAND; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY ANALYSIS; SIMULATION; SWEDEN;

EID: 67650410006     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0146     Document Type: Article

References (25)

1. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-72.
2. Hakama M. Screening. In: Holland WW, Knox R, Detels G, editors. Oxford textbook of public health. 2nd ed. Oxford University Press (Oxford); 1991.
3. Day NE. Estimating the sensitivity of a screening test. J Epidemiol Community Health 1985;39:364-6.
4. Labrie F, Dupont A, Suburu R, et al. Serum prostate-specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:847-51.
5. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Fam Pract 2003;16:95-101.
6. Määttänen L, Hakama M, Tammela T, et al. Specificity of serum prostate specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer 2007;96:56-60.
7. Van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst 2003;94:1462-4.
8. Punglia RS, d'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
9. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml lower. JAMA 2005;294:66-7.
10. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostate cancer. JAMA 1995;273:289-94.
11. Parkes C, Wald NJ, Murphy P, et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. Br Med J 1995;311:1340-3.
12. Wald NJ, Watt WC, George L, Knekt P, Helzlsouer KJ, Tuomilehto J. Adding free to total prostate specific antigen levels in trials of prostate cancer screening. Br J Cancer 2000;82:731-6.
13. Hakama M, Stenman UH, Aromaa A, Leinonen J, Hakulinen T, Knekt P. Validity of the prostate specific antigen test for prostate cancer screening: follow-up study with a bank of 21,000 sera in Finland. J Urol 2001;166:2189-91.
14. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. Lyon; IARC: 2002.
15. Hakama M, Auvinen A, Day NE, Miller AB. Sensitivity in cancer screening. J Med Screen 2007;14:174-7.
16. Auvinen A, Määttänen L, Finne P, et al. Test sensitivity of serum prostate specific antigen in the Finnish prostate cancer screening trial. Int J Cancer 2004;111:940-3.
17. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
18. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993;85:1644-56.
19. Cervix cancer screening. IARC handbooks for cancer prevention, vol. 10. Lyon; IARC: 2005.
20. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
21. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
22. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397-405.
23. Otto SJ, van der Cruijsen IW, Liem MK, et al. Effective PSA contamination in the Rotterdam section of the European Randomised Study of Screening for Prostate Cancer. Int J Cancer 2003;105:394-9.
24. Teppo L, Pukkala E, Lehtonen M. Data quality and quality control at a population-based cancer registry. Acta Oncol 1994;33:365-9.
25. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register. Acta Oncol 2009;48:27-33.